fexofenadine has been researched along with quinidine in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (6.67) | 18.2507 |
2000's | 4 (26.67) | 29.6817 |
2010's | 8 (53.33) | 24.3611 |
2020's | 2 (13.33) | 2.80 |
Authors | Studies |
---|---|
Cvetkovic, M; Fromm, MF; Kim, RB; Leake, B; Wilkinson, GR | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Kawabata, T; Kitamura, Y; Koto, H; Kusuhara, H; Matsuura, S; Sugiyama, Y; Tsuchiya, H; Tsujimoto, H | 1 |
Deshmukh, SV; Durston, J; Shomer, NH | 1 |
Beale, KK; Bertino, JS; Ma, JD; Nafziger, AN; Trivedi, M; Tsunoda, SM | 1 |
Kataoka, M; Masaoka, Y; Sakuma, S; Yamashita, S; Yokoyama, T | 1 |
Ito, S; Iwamoto, K; Kamimura, H; Mizunaga, M; Nakayama, K; Negoro, T; Nishiwaki, M; Nomura, Y; Suemizu, H; Yamazaki, H; Yoneda, N | 1 |
Chang, H; Chen, C; Du, H; Guan, C; Li, C; Qiu, L; Wang, S; Wang, T; Wu, Y; Zhang, L; Zhang, S; Zhou, H | 1 |
3 review(s) available for fexofenadine and quinidine
Article | Year |
---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Digoxin; Drug Interactions; Genotype; Humans; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Prescription Drugs; Propanolamines; Quinidine; Reproducibility of Results; Terfenadine | 2010 |
12 other study(ies) available for fexofenadine and quinidine
Article | Year |
---|---|
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Carrier Proteins; Genes, MDR; HeLa Cells; Histamine H1 Antagonists; Humans; LLC-PK1 Cells; Mice; Rats; Swine; Terfenadine; Tissue Distribution; Transfection; Vaccinia virus | 1999 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Dogs; Female; Intestinal Absorption; Loperamide; Male; Mutation; Quinidine; Terfenadine | 2008 |
Validation of the use of nonnaive surgically catheterized rats for pharmacokinetics studies.
Topics: Animals; Antipyrine; Catheterization; Cost-Benefit Analysis; Femoral Artery; Hematocrit; Jugular Veins; Male; Pharmacokinetics; Quinidine; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Surgical Procedures, Operative; Terfenadine; Time Factors; Triazoles | 2008 |
Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation.
Topics: Algorithms; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Drug Interactions; Erythromycin; Gene Expression; Glycerol; Humans; Intestinal Absorption; Loperamide; Models, Biological; Pharmaceutical Preparations; Propanolamines; Puromycin; Quinidine; Saquinavir; Solubility; Surface-Active Agents; Terfenadine; Verapamil; Vinblastine | 2011 |
Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data.
Topics: Acetamides; Albuterol; Animals; Carbamates; Chromatography, Liquid; Diazepam; Diclofenac; Digitoxin; Humans; Itraconazole; Ketoprofen; Liver; Metabolic Clearance Rate; Mice; Mice, Transgenic; Naproxen; Pharmaceutical Preparations; Phenytoin; Piperidines; Pravastatin; Pyrimidines; Quinidine; Tandem Mass Spectrometry; Telmisartan; Terfenadine; Verapamil | 2020 |
Effects of membrane transport activity and cell metabolism on the unbound drug concentrations in the skeletal muscle and liver of drugs: A microdialysis study in rats.
Topics: Animals; Antipyrine; Atenolol; Carbamazepine; Cell Membrane; Digoxin; Diltiazem; Diphenhydramine; Drug Elimination Routes; Gabapentin; Lamotrigine; Liver; Memantine; Membrane Transport Proteins; Microdialysis; Muscle, Skeletal; Ofloxacin; Pharmaceutical Preparations; Propranolol; Pyrilamine; Quinidine; Rats; Terfenadine | 2021 |